Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.40 |
| ▸ | CDK2 | P24941 | 9/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7883682 | 0.91 | CHEK1 (0.41) | JAK1JAK3HSP90AA1CHEK1CCNA2 | |
| SCHEMBL7874894 | 0.90 | MAP4K4 (0.41) | JAK1JAK3CHEK1CCNA2CDK2 | |
| SCHEMBL7874811 | 0.90 | CHEK1 (0.49) | HSP90AA1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7879813 | 0.90 | CHEK1 (0.40) | HSP90AA1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL6892935 | 0.89 | CHEK1 (0.40) | HSP90AA1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7874807 | 0.89 | CHEK1 (0.39) | JAK1JAK3HSP90AA1CHEK1CCNA2 | |
| SCHEMBL7883136 | 0.89 | JAK1 (0.41) | JAK1JAK3HSP90AA1CHEK1CCNA2 | |
| SCHEMBL7879086 | 0.88 | CHEK1 (0.39) | HSP90AA1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7886590 | 0.88 | CHEK1 (0.39) | HSP90AA1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7883158 | 0.88 | CHEK1 (0.38) | JAK1JAK3HSP90AA1CHEK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | JAK1 4716/4885JAK3 4808/4885HSP90AA1 2012/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | JAK1 735/4885JAK3 1349/4885HSP90AA1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.